Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05197192
Title A Prospective, Open-label, Multicentre, Randomized, Phase-3-trial of Acalabrutinib, Obinutuzumab and Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk Chronic Lymphatic Leukemia
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors German CLL Study Group

chronic lymphocytic leukemia/small lymphocytic lymphoma


Obinutuzumab + Venetoclax

Acalabrutinib + Obinutuzumab + Venetoclax

Age Groups: adult | senior
Covered Countries DEU

No variant requirements are available.